

AMENDMENTS

In the claims:

Please amend the claims to read as follows:

B¹

21. (Amended) A method of treating inflammatory bowel disease, comprising:
administering a therapeutically effective amount of a therapeutic composition comprising 1 α -hydroxyvitamin D₃ to a subject suffering from the symptoms of inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn's disease.

B²

29. (Amended) A method of treating inflammatory bowel disease, comprising:
administering a therapeutically effective amount of a therapeutic composition comprising 1 α -hydroxyvitamin D₂ to a subject suffering from the symptoms of inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn's disease.

B³

37. (Amended) A method of treating inflammatory bowel disease, comprising:
administering a therapeutically effective amount of a therapeutic composition comprising 19-nor-1,25-dihydroxyvitamin D₂ to a subject suffering from the symptoms of inflammatory bowel disease, wherein said inflammatory bowel disease is selected from the group consisting of ulcerative colitis and Crohn's disease.

Support for the amendments the claims can be found throughout the application as filed, including, but not limited to, the abstract ("[m]ethods of treating inflammatory bowl disease... involve administration of biologically active vitamin D compounds and therapeutic compositions thereof") and paragraph 29 ("[i]n one embodiment, the biologically active vitamin D compound is selected from... 1 α -hydroxyvitamin D₃... 1 α -hydroxyvitamin D₂, [and] 19-nor-1,25-dihydroxyvitamin D₂")